← All trials
NCT04446130
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2019
- Primary completion
- Jan 1, 2023
- Completion date
- Jan 1, 2024
- First posted
- Jun 24, 2020
- Last posted
- Jun 24, 2020
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Soochow UniversityLead sponsor
- Anhui Medical UniversityCollaborator
- Soochow UniversityOverall official - principal investigator
- Nanjing UniversityCollaborator
- Shenzhen UniversityCollaborator
- Henan Medical UniversityCollaborator
- Shandong Provincial HospitalCollaborator
- Changzhou No.2 People's HospitalCollaborator
- The Second People's Hospital of Huai'anCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.